What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings?
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Holocene Advisors Brandon Haley | 4,164,438 | $511,143,120 | +60% | 1.07% |
| 2. | Citadel Investment Group Ken Griffin | 3,887,520 | $477,154,205 | -26% | 0.07% |
| 3. | Renaissance Technologies Jim Simons | 2,788,728 | $342,288,475 | -49% | 0.53% |
| 4. | AQR Capital Management Cliff Asness | 2,694,944 | $330,777,425 | +14% | 0.17% |
| 5. | GLG Partners Noam Gottesman | 1,725,112 | $211,740,247 | -2% | 0.36% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $155.62 | 200 | $31,124.00 | 120,288 | 2026-02-17 | Filing | |
| $154.91 | 9,395 | $1,455,384.15 | 120,488 | 2026-02-17 | Filing | |
| $154.18 | 18,405 | $2,837,719.71 | 129,883 | 2026-02-17 | Filing | |
| $154.43 | 3,000 | $463,290.00 | 167,779 | 2026-02-17 | Filing | |
| $150.00 | 115,640 | $17,346,000.00 | 613,912 | 2026-02-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 123,195,578 | $15,121,025,249 | 0.26% | |
| 2. | 121,097,336 | $14,863,487,020 | 0.22% | |
| 3. | 65,579,490 | $8,049,226,574 | 0.41% | |
| 4. | 60,240,518 | $7,393,921,179 | 0.25% | |
| 5. | 42,872,129 | $5,262,268,432 | 0.72% |
News See All
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets and what may drive ...
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 - Here's Why
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2025 Earnings Call Transcript
Rebecca: Afternoon, everyone, and welcome to Gilead Sciences, Inc.'s Fourth Quarter and Full Year 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD.
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating
Gilead Sciences, Inc. (NASDAQ:GILD) is among the 12 Most Profitable NASDAQ Stocks to Buy Right Now.
UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook
Gilead Sciences, Inc. (NASDAQ:GILD) is among the most profitable healthcare stocks to buy. On January 26, UBS lifted the price target on Gilead Sciences, Inc.
12 Most Profitable NASDAQ Stocks to Buy Right Now
2025 was another stellar year for the markets, marking the third successive instance of double-digit returns for the indices.
10 Most Profitable Healthcare Stocks to Buy
By far, the healthcare sector remains among the most resilient and profitable in global equity markets.
Hedge Fund Resource Center Billionaire Hedge Funds
